重度哮喘治疗药物benralizumab的药理及临床评价  

Pharmacological effects and clinical evaluation of benralizumab in the treatment of severe asthma

作　　者：李朗 封宇飞[1] 王志宏[1] LI Lang;FENG Yu-fei;WANG Zhi-hong(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing 100730,China)

机构地区：[1]北京医院药学部药物临床风险与个体化应用评价北京市重点实验室国家老年医学中心,北京100730

出　　处：《中国新药杂志》2019年第10期1169-1171,共3页Chinese Journal of New Drugs

摘　　要：benralizumab是一种IgG1k型人源化单克隆抗体,具有抗白介素-5α受体作用。2017年11月14日,FDA批准本品上市,用于12岁及以上重度哮喘患者的附加维持治疗。本文就其作用机制、药效学、药动学、临床评价、安全性、用法用量等进行综述,旨在为临床合理使用提供参考。Benralizumab is a humanized monoclonal antibody of IgG1k type which is able to bind to the IL-5 receptor(IL-5R)α chain. It was approved by FDA in November 2017,which is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older. In this paper,the action mechanism,pharmacokinetics,drug interactions,clinical evaluation,safety,pharmacokinetics and applications of benralizumab are summarized for the purpose of providing reference for clinical treatments.

关 键 词：benralizumab 人源化单克隆抗体 重度哮喘 白介素-5α受体 药理作用 临床评价 

分 类 号：R974.3[医药卫生—药品]